Nonadherence, Diversion, or Analytical Limitation? A Negative Urine Opiate Screen in a Patient Prescribed Hydrocodone

Abstract

Urine drug testing is commonly used to assess adherence to prescribed opioid therapy. We describe a patient prescribed hydrocodone/acetaminophen who reported recent use but had negative urine opiate and oxycodone immunoassay screens, raising concerns regarding nonadherence or diversion. Because the screening results were inconsistent with the medication history, definitive testing by liquid chromatography–tandem mass spectrometry (LC-MS/MS) was specifically requested. LC-MS/MS detected hydrocodone, norhydrocodone, and hydromorphone, confirming recent drug ingestion and expected metabolism. The negative screening results were attributed to limited immunoassay cross-reactivity with hydrocodone and its metabolites and to analyte concentrations below the immunoassay detection threshold. Importantly, a negative immunoassay screening result does not necessarily indicate absence of drug in the specimen; it indicates only that the analyte was not detected above the assay cutoff. Because LC-MS/MS methods often have greater analytical sensitivity and lower detection limits than screening immunoassays, drugs and metabolites may be detected despite a negative screen. Understanding assay limitations and testing algorithms is essential to avoid misclassifying adherent patients as nonadherent and to support appropriate clinical decision-making.